fluorodeoxyuridine + mitomycin c

This is a combination chemotherapy regimen consisting of fluorodeoxyuridine (also known as floxuridine or FUDR) and mitomycin C. Both are small molecule antineoplastic agents used together for the treatment of various cancers. Fluorodeoxyuridine is a pyrimidine analog that inhibits thymidylate synthase, thereby blocking DNA synthesis in rapidly dividing cells. Mitomycin C is an alkylating agent that crosslinks DNA, leading to inhibition of DNA synthesis and function. The combination has been studied as palliative therapy for unresectable primary liver cancer (administered intrahepatically), metastatic colorectal cancer (as salvage therapy), and other solid tumors[1][3][4]. The regimen may also be considered in settings where other chemotherapies have failed or are not tolerated.

Brand names

MutamycinJelmytoMitosol

Other names

FUDR + mitomycin Cfloxuridine + mitomycin C5-fluoro-2'-deoxyuridine + mitomycin C